Key Drivers
- Strong liquidity
- Improving profitability
- Persistent cash burn
AIAI Summary
TBPH has shifted from a binary clinical gamble to a cash‑generative, restructuring-led commercial story where near-term value is now driven by realization of ~ $400M cash runway (Trelegy/YUPELRI milestones) and delivery of $60–70M annualized cost savings. Actionable thesis: monitor milestone receipts and Q3‑2026 proof of cost‑run execution as the primary catalysts — missed milestones, failed savings implementation, or adverse legal outcomes would rapidly reintroduce severe financing and valuation risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Improving profitability
- •Persistent cash burn
TBPH's liquidity and leverage materially improved (cash $175.6M, current ratio 9.48, debt/equity 0.79) and profitability moved toward break-even in the quarter, but persistent negative free cash flow and a large accumulated deficit keep execution and cash-burn risk elevated.
Price Behavior
Key Price Behavior Insights:
- •Sharp downshift
- •Short-term base
- •Near-term resistance
Over the last month TBPH plunged ~25–30% from about $19.66 to $14.33, then formed a mid-March base near $13.5–$13.9 with resistance at $14.0–$14.5 (structural cap $19–$20), and a break above $14.5 would favor tactical momentum entries.
Rapid ~25–30% drop from ~$19.66 to ~$14.33 over the last month
Sentiment & News
Key News Insights:
- •Trial failure
- •Strategic review
- •Strong cash position
Theravance's Phase 3 ampreloxetine failure triggered a 26% stock drop, program termination and a strategic-review/sale process with cost cuts despite a strong near-term cash runway and ongoing legal/investor scrutiny.
The clinical setback raises near-term valuation and execution risk despite sufficient liquidity to fund restructuring and potential sale options
Similar Companies in Healthcare
Other companies in the same sector with AI ratings